Search Results
Jun 29, 2026, 13:30 ET Plopii lanza sobres nootrópicos para la concentración sin nicotina, potenciados con paraxantina
concentración, con un perfil más suave para el sueño, la ansiedad y la tolerancia.La fórmula combina paraxantina con 60 mg de alfa-GPC, 60 mg de citicolina y 60 mg de L-teanina, una combinación diseñada para favorecer la atención y una energía tranquila y concentrada durante todo el día."Creamos
More news about: Plopii Inc.
Jun 29, 2026, 13:28 ET Plopii bringt nikotinfreie „Focus"-Beutel mit nootropischer Wirkung auf den Markt, deren Wirkstoff Paraxanthin ist
milderen Auswirkungen auf den Schlaf, die Angstempfindung und die Toleranzentwicklung.Die Formel kombiniert Paraxanthin mit 60 mg Alpha-GPC, 60 mg Citicolin und 60 mg L-Theanin – eine Kombination, die darauf ausgelegt ist, die Aufmerksamkeit sowie eine ruhige, konzentrierte Energie über den ganzen
More news about: Plopii Inc.
Jun 29, 2026, 12:21 ET Plopii lance des sachets « Focus » nootropiques sans nicotine, à base de paraxanthine
un profil d'action plus doux en matière de sommeil, d'anxiété et de tolérance.Cette formule associe la paraxanthine à 60 mg d'Alpha-GPC, 60 mg de citicoline et 60 mg de L-théanine, une combinaison conçue pour favoriser la concentration et procurer une énergie sereine et ciblée tout au long de
More news about: Plopii Inc.
Jun 29, 2026, 11:13 ET Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression
Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in September 2025.VANCOUVER, BC,
More news about: Optimi Health Corp
Jun 29, 2026, 10:41 ET Plopii Launches Nootropic Nicotine-Free Focus Pouches Powered by Paraxanthine
energy and clearer focus with a gentler profile for sleep, anxiety, and tolerance.The formula pairs paraxanthine with 60mg of Alpha-GPC, 60mg of Citicoline, & 60mg of L-theanine, a combination designed to support attention and calm, focused energy throughout the day."We built Plopii
More news about: Plopii Inc.
Jun 29, 2026, 10:31 ET Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight
apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor, in patients with FSGS. The study demonstrated that the 20 mg dose of apecotrep reduced proteinuria by 40% compared with placebo.What is Nephrotic Syndrome?Nephrotic syndrome is a kidney
More news about: DelveInsight Business Research, LLP
Jun 29, 2026, 10:27 ET Plopii Launches Nootropic Nicotine-Free Focus Pouches Powered by Paraxanthine
energy and clearer focus with a gentler profile for sleep, anxiety, and tolerance.The formula pairs paraxanthine with 60mg of Alpha-GPC, 60mg of Citicoline, & 60mg of L-theanine, a combination designed to support attention and calm, focused energy throughout the day."We built Plopii
More news about: Plopii Inc.
Jun 29, 2026, 08:00 ET 禮邦醫藥（09637.HK）正式在香港聯合交易所主板掛牌上市
st-in-class）泛磷酸鹽轉運蛋白抑制劑，已獲NMPA突破性治療藥物（BTD）認定，並將中國大陸、香港、澳門及台灣以外權益授權予R1 Therapeutics。中國II期數據顯示，AP306單藥治療可使平均血清磷較基線下降2.51 mg/dL，約95%的患者在第7至8周將血清磷控制於5.5 mg/dL以下，而同期陽性對照碳酸司維拉姆組這一比例約為50%。AP303為同類首創（first-in-class）差異化雙重PPAR激動劑，旨在延緩或阻止CKD進展，潛在覆蓋適應症包括糖尿病腎病（DKD）與IgA腎病（IgAN）等，已獲美國FDA授予的常染色體顯性多囊性腎病（ADP
More news about: 禮邦醫藥
Jun 29, 2026, 08:00 ET Alebund Pharmaceuticals (09637.HK) Debuts on the HKEx Main Board
licensed to R1 Therapeutics. China Phase II data demonstrated monotherapy reducing mean serum phosphate by 2.51 mg/dL from baseline and approximately 95% of patients achieving serum phosphate below 5.5 mg/dL by Week 7-8 (versus approximately 50% for the active control, sevelamer carbonate, in the same trial).AP303
More news about: Alebund Pharmaceuticals
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption
More news about: Nuvation Bio Inc.
Jun 29, 2026, 07:30 ET Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Figure 2: In a Phase 1 patient expansion study, BHV-1300 (1,000 mg SC weekly) rapidly removed more than 80% of disease-driving TSHR autoantibodies (TRAb) — the root cause of Graves' disease — and normalized free T4 and
More news about: Biohaven Ltd.
Jun 29, 2026, 06:59 ET Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy
total of 39 participants who were treated with 16 mg of VR-205 daily (four capsules) over a nine-month treatment period.Following completion of treatment, participants entered a three-month follow-up period including a two-week dose tapered to 8 mg of VR-205 (two capsules) daily at the start of the
More news about: Viatris Inc.
Jun 29, 2026, 03:58 ET Positive interim analysis advances Avecho Phase III insomnia program
insomnia."The interim analysis was conducted on data from 244 participants randomised across three treatment groups receiving nightly doses of either 150mg CBD, 75mg CBD or placebo in a TPM®-enhanced capsule over an eight-week treatment period.Safety data reviewed at the interim analysis further supported
More news about: Avecho Biotechnology Limited
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were
More news about: AbbVie
Jun 26, 2026, 16:50 ET SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
provider tells you to use it.SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.This is
More news about: AbbVie
Jun 26, 2026, 16:00 ET Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
intense pain.[2] Approximately 200,000 people in the United States suffer from uncontrolled gout, with serum uric acid (sUA) levels above 6 mg/dL and persistent, debilitating flares and/or tophi despite treatment with oral urate-lowering therapies.[3],[4] Elevated
More news about: Swedish Orphan Biovitrum AB
Jun 26, 2026, 15:59 ET Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)
intense pain.[2] Approximately 200,000 people in the United States suffer from uncontrolled gout, with serum uric acid (sUA) levels above 6 mg/dL and persistent, debilitating flares and/or tophi despite treatment with oral urate-lowering therapies.[3],[4] Elevated
More news about: Swedish Orphan Biovitrum AB
Jun 26, 2026, 12:35 ET Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
quantifies MG disease severity through muscle weakness. The total QMG score ranges from 0 to 39, where higher scores indicated greater disease severity.12i. At Week 24, patients with MG-ADL scores lower than 9 treated with IMAAVY plus SOC achieved greater reductions in MG-ADL scores
More news about: Johnson & Johnson
Jun 26, 2026, 09:31 ET Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
Enzalutamide Tablets, 40 mg and 80 mg as bioequivalent to reference listed drug (RLD) Xtandi® Tablets of Astellas for the indication in the approved labeling. While Xtandi Tablets are traditionally available in 40 mg and 80 mg strengths, Lupin's tentatively approved 120 mg and 160 mg strengths will provide
More news about: Lupin Pharmaceuticals, Inc.
Jun 26, 2026, 09:30 ET A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
data readout in Q4 2026.Company-reported Phase 2 results showed a ~23-point MADRS reduction from baseline at 12 months (after two 16 mg doses three weeks apart), with response/remission rates of 75% at week 18 improving to 100% response and 71% remission at 12 months — figures
More news about: USA News Group
Jun 26, 2026, 07:16 ET Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
lymphoma (MCL) and chronic lymphocytic leukemia (CLL).2,3 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.About Chronic Lymphocytic Leukemia (CLL)
More news about: Eli Lilly and Company
Jun 26, 2026, 02:00 ET 2026 ASCAP TOP RHYTHM & SOUL MUSIC AWARD WINNERS INCLUDE SONGWRITER OF THE YEAR MUSTARD, R&B/HIP-HOP AND RAP SONG OF THE YEAR "LUTHER," GOSPEL SONG OF THE YEAR "REST ON US," AND PUBLISHER OF THE YEAR SONY MUSIC PUBLISHING
earns the ASCAP R&B/Hip-Hop and Rap Song of the Year. Published by BMG, Universal Music Publishing Group, Sony Music Publishing, FCG Music, MG III Music and NMG Music, the standout single soared to the top of the Billboard Hot 100 chart, spending a total of 13 weeks at #1. It broke the record
More news about: ASCAP - American Society of Composers, Authors and Publishers